– All 50 States having the approved label for TOMI’s BIT™ validates claims for its effectiveness in addressing
some of the most harmful pathogens* in hospitals; C. diff+, MRSA**and H1N1** –
– Increases market potential with hospitals and healthcare networks –
BEVERLY HILLS, Calif., Oct. 03, 2016 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (OTCQX:TOMZ) (TOMI), a global bacteria decontamination and infection
prevention company, announced it received an amended label for its Binary Ionization Technology (BIT™) from the NY State Department
of Environmental Conservation. With the amended label, TOMI is approved to directly market to healthcare networks in New York and
across all 50 states the addition of specific claims against the organisms Clostridium difficile spores (C. diff) +,
Methicillin Resistant Staphylococcus aureus (MRSA)**and influenza (H1N1)**.
“Garnering the amended EPA label approval in New York State is a significant milestone,” said Dr. Halden Shane, TOMI’s Chief
Executive Officer. “Once again, we have passed another level of rigorous testing and received validation for our technology.
With this label, we gained access to a sizable healthcare network and plan to aggressively market to the Empire State.
Further, in all 50 states we have achieved status to specifically market our quick and cost effective method to achieve health,
safety and risk management benefits by disinfecting indoor space and surfaces with the SteraMist BIT platform."
TOMI received its initial EPA registration (no. 90150-2) for BIT in June 2015, for use as a healthcare-hospital disinfectant.
Its label was amended in February 2016 to include its effectiveness in disinfecting Clostridium difficile (C. diff)
spores+, Methicillin Resistant Staphylococcus aureus (MRSA) **, and influenza (H1N1)
**, which are three of the most prevalent, harmful and costly pathogens facing healthcare systems worldwide.
TOMI’s SteraMist BIT is currently registered in 50 states to date. The SteraMist BIT brand of products includes the SteraMist
Surface Unit, which is a handheld, point-and-spray application, and SteraMist Environment System, which is a complete room fogging
system. More information on TOMI’s complete suite of SteraMist BIT products can be found at www.tomimist.com or below.
Source Materials
+Clostridium difficile spores (C. diff) (ATCC# 43598) test conducted
with SteraMist™ Environment System.
** Methicillin Resistant Staphylococcus aureus (MRSA), influenza (H1N1) test conducted
with SteraMist Surface Unit.
* Pathogens: SteraMist disinfects against Clostridium difficile spores (C. diff) (ATCC# 43598),
Methicillin Resistant Staphylococcus aureus (MRSA) (ATCC# 33592), and Influenza A (H1N1) virus (ATCC VR-1469).
About TOMI™ Environmental Solutions, Inc.
TOMI™ Environmental Solutions, Inc. (OTCQX:TOMZ) is a global bacteria decontamination and infectious disease control
company, providing eco-friendly environmental solutions for indoor surface decontamination through manufacturing, sales and
licensing of our premier platform of Hydrogen Peroxide based products that uses Binary Ionization Technology® (BIT™) , a
state of the art technology for the production of its six-log mist represented by the TOMI™ SteraMist™ brand.
TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities,
cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing
facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and
multi-unit residences.
TOMI also develops training programs and application protocols for its clients and is a member in good standing with The
American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection
Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality
Association, and The International Ozone Association. For additional product information, visit www.tomimist.com or contact us at info@tomimist.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities
Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we
expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,”
“projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements
addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including
statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements
within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors
that could cause our actual results to differ materially from our anticipated results. The information provided in this document is
based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements
after the date of this release.
INVESTOR RELATIONS CONTACT:
Becky Herrick & Kirsten Chapman
LHA Investor Relations
(415) 433-3777
tomi@lhai.com
MEDIA RELATIONS CONTACT:
Aaron Loveland
VP of Marketing and Public Affairs
(240) 672-6263
aloveland@tomimist.com
